Surrozen, Inc. (NASDAQ:SRZN – Get Free Report) major shareholder Tcg Crossover Gp Ii, Llc bought 35,433 shares of the company’s stock in a transaction that occurred on Friday, March 13th. The shares were acquired at an average cost of $24.88 per share, with a total value of $881,573.04. Following the transaction, the insider owned 675,018 shares in the company, valued at approximately $16,794,447.84. This represents a 5.54% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Tcg Crossover Gp Ii, Llc also recently made the following trade(s):
- On Monday, March 16th, Tcg Crossover Gp Ii, Llc acquired 1,190 shares of Surrozen stock. The shares were bought at an average price of $24.99 per share, for a total transaction of $29,738.10.
- On Thursday, March 12th, Tcg Crossover Gp Ii, Llc bought 12,374 shares of Surrozen stock. The shares were purchased at an average cost of $24.99 per share, for a total transaction of $309,226.26.
- On Thursday, February 12th, Tcg Crossover Gp Ii, Llc acquired 1,093 shares of Surrozen stock. The stock was purchased at an average price of $23.86 per share, for a total transaction of $26,078.98.
- On Wednesday, February 11th, Tcg Crossover Gp Ii, Llc purchased 17,763 shares of Surrozen stock. The stock was acquired at an average price of $23.57 per share, for a total transaction of $418,673.91.
- On Tuesday, February 3rd, Tcg Crossover Gp Ii, Llc acquired 4,355 shares of Surrozen stock. The shares were acquired at an average price of $21.94 per share, for a total transaction of $95,548.70.
- On Monday, February 2nd, Tcg Crossover Gp Ii, Llc purchased 731 shares of Surrozen stock. The stock was bought at an average price of $21.38 per share, with a total value of $15,628.78.
- On Friday, January 30th, Tcg Crossover Gp Ii, Llc acquired 4,271 shares of Surrozen stock. The shares were bought at an average cost of $21.39 per share, with a total value of $91,356.69.
Surrozen Trading Up 1.2%
Surrozen stock traded up $0.29 during midday trading on Monday, hitting $25.50. The stock had a trading volume of 33,763 shares, compared to its average volume of 112,361. The stock has a market cap of $218.56 million, a P/E ratio of -1.14 and a beta of 0.53. The business has a fifty day moving average price of $23.46 and a 200 day moving average price of $18.20. Surrozen, Inc. has a 12 month low of $5.90 and a 12 month high of $29.59.
Wall Street Analyst Weigh In
Read Our Latest Analysis on Surrozen
Institutional Trading of Surrozen
Large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its position in Surrozen by 22.6% during the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock worth $277,000 after acquiring an additional 5,702 shares during the period. Stonepine Capital Management LLC raised its stake in shares of Surrozen by 7.1% during the second quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock valued at $2,736,000 after purchasing an additional 20,247 shares in the last quarter. Stempoint Capital LP lifted its holdings in Surrozen by 185.1% in the second quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock worth $6,138,000 after purchasing an additional 445,713 shares during the period. Armistice Capital LLC acquired a new stake in Surrozen in the second quarter worth about $536,000. Finally, Braidwell LP bought a new position in Surrozen in the 2nd quarter valued at about $1,252,000. 66.57% of the stock is currently owned by institutional investors and hedge funds.
About Surrozen
Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.
The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.
Read More
- Five stocks we like better than Surrozen
- The “secret weapon” behind Microsoft, Meta, Amazon, and Google
- A personal warning from Martin Weiss (Please read)
- Elon Musk: This Could Turn $100 into $100,000
- Only 500 people today…
- Central banks just did something they haven’t done since 1967
Receive News & Ratings for Surrozen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surrozen and related companies with MarketBeat.com's FREE daily email newsletter.
